{"organizations": [], "uuid": "0b6f993bf6b1b6ba9318eefe7e9c3ca26d8e6a17", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-fda-approves-ultragenyx-pharmaceut/brief-fda-approves-ultragenyx-pharmaceuticals-crysvita-to-treat-an-inherited-form-of-rickets-idUSFWN1RU161", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Approves Ultragenyx Pharmaceutical's Crysvita To Treat An Inherited Form Of Rickets", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T21:06:00.000+03:00", "replies_count": 0, "uuid": "0b6f993bf6b1b6ba9318eefe7e9c3ca26d8e6a17"}, "author": "", "url": "https://www.reuters.com/article/brief-fda-approves-ultragenyx-pharmaceut/brief-fda-approves-ultragenyx-pharmaceuticals-crysvita-to-treat-an-inherited-form-of-rickets-idUSFWN1RU161", "ord_in_thread": 0, "title": "BRIEF-FDA Approves Ultragenyx Pharmaceutical's Crysvita To Treat An Inherited Form Of Rickets", "locations": [], "entities": {"persons": [], "locations": [{"name": "hypophosphatemia", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "ultragenyx pharmaceutical", "sentiment": "negative"}, {"name": "treat an inherited form of rickets reuters", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17, 2018 / 6:08 PM / Updated 7 minutes ago BRIEF-FDA Approves Ultragenyx Pharmaceutical's Crysvita To Treat An Inherited Form Of Rickets Reuters Staff 1 Min Read \nApril 17 (Reuters) - U.S. Food and Drug Administration: \n* U.S. FDA SAYS APPROVED CRYSVITA (BUROSUMAB) TO TREAT ADULTS & CHILDREN AGES 1 YEAR& OLDER WITH X-LINKED HYPOPHOSPHATEMIA, AN INHERITED FORM OF RICKETS \n* U.S. FDA SAYS GRANTED APPROVAL OF CRYSVITA TO ULTRAGENYX PHARMACEUTICAL INC Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-17T21:06:00.000+03:00", "crawled": "2018-04-17T21:23:33.016+03:00", "highlightTitle": ""}